FDA Approves INQOVI — Taiho Pharmaceutical Co., Ltd.

# FDA Approves Taiho Pharmaceutical's INQOVI, First Oral Combination Therapy for Myelodysplastic Syndromes Taiho Pharmaceutical Co., Ltd. received FDA approval for INQOVI (cedazuridine and decitabine), marking a significant shift in the myelodysplastic syndrome market by offering the first oral formulation of a DNA methyltransferase inhibitor combination, potentially expanding treatment accessibility and improving patient compliance compared to intravenous alternatives. The approval positions Taiho to capture market share in the estimated